Anavex Life Sciences Corporation (AVXL) 옵션

I do have an issue. I have an issue with arrogant, patronizing posts by a narcissist who is threatened by anyone who receives attention or respect on this message board, and who self soothes with venomous personal attacks to restore a sense of self worth. I think just about everyone here shares my issue.

Can Christopher Missling get to work as the fda director one day?

Is that calendar days or working days?

Please, have the last word. I'm sure you have one more condescending comment in you.

Scott Gottlieb is on the board of directors at pfizer. Gee him working at yhe fda as director had nothing to do with him hetting that hard job at pfe. Thats real hard working on those board of directors he may have to take out a note pad and write someyhong important.

Thats my birthday too. Wow you dhould have told me. Happy Birthda.

Ask yourself where Scott Gottlieb works after being the fda director?

Thanks for clarifying the entire cost of thst medicine that has side effects. Brain swelling and brain bleeding

How much should one 50 mg capsule of Anavex’s blarcamesine cost on average in the EU, European Union.

Good luck and GOD bless,

The one thing I'd like to add is that it is another example of how BP has more wherewithal and whatever to get agencies to ho along.  Small fry bio is up against it. 

mauismart:

That $26500 is I believe just the yearly cost of the MAB biologic to be infused according to the schedule and not the cost of the actual infusions and retail of the infusion space and not included nurses who perform the infusion and not include the cost of MRI imaging, etc, etc, etc.

Good luck and GOD bless.

How many days is that from the submission date?
You see?

You've been helped many times. Clearly your issue lies elsewhere.

Chin up. Don't be hurt.

26500 dollars annually for leqembi. Injections. Can you believe europe approves this before anavex medicine.

Esai"s medicine for alzheimer was approved in Europe. Lets compare anavex medicine with that.

Georgii good for you. In what “good book” do you find perpetuating the aggravation of anonymous rebel rousers on a message board morally supported?

Mine tells me to shake the dust off of my sandal's and move on.

Pride is a dangerous thing. Time to turn a new leaf.

Tred

Here is a link to an Alzheimer disease CME presentation Dr. Sabbagh did a couple months ago. he discusses inflammatory mechanisms, drugs in phase 2/phase 3 and the anti-amyloid mAbs

https://lrn.peerview.com/150210209

Lots of Blarcamesine News After EMA Acts
I only wish all of what you posted was delivered to us by someone in management.
When the time is right Missling and company will be telling the details of what I posted. Probably when the European Medicines Agency hints at or gives its first approval of blarcamesine. When the EMA acts there will be a backed-up flood of blarcamesine news releases that will be in the popular news media.

When any of this begins, common, retail stock investors will take notice and the AVXL share price will ascend steeply.

I guess you missed all the great releases by management. smh

Great.  I only wish all of what you posted was delivered to us by someone in management.  At least we ran up to the close

Solid close. I will take it and see if it continues the current trend.
Gotta go back 6 months to see 3 volume bars in a row this short.
Green 100period basically flat. Flat is easier to break through than down angled. Maybe that will help here at 9.29ish today.

https://investorshub.advfn.com/uimage/uploads/2025/4/15/thvikScreen_Shot_2025-04-15_at_5.47.29_PM.png

There's 0% of withdrawl by Anavex IMO and if i calculate the odd for approval VS reject
97.4%/ (0.8% + 97.4%) = 99.2%
99%!!!!
trying to jack it up. : )

Anavex’s blarcamesine really works



Good luck and GOD bless,

It has been suggested that the EMA's very restricted approval of leqembi somehow signals that blarcasamine will not be approved. To the contrary ,limiting leqembi to about 30% of the population because of serious ARIA concerns, and requiring a lot of administration regulations is signaling the need for a better Alzheimer drug!
Blarcamesine is that drug! No ARIA! No brain swelling. No brain bleeds. No deaths! Safer, more effective and far cheaper!
Europe needs a better drug than the Mabs...and is within some months(not years!) of approval of blarcamesine!
European approval will lead to approvals in Australia, the UK and Canada. And the huge Asia-Pacific area will follow. Discussions with health officials are already under way.
And any time the FDA gets its act together...the US will get on board!
Can you imagine the size of the world-wide partnership(s)?
Multi-billions! APPROVALS and PARTNERSHIPS and SALES will soon be driving the share price! 2025 is the pivotal year!

falconer66a , thanks for the great summary of Blarcamesines positive outcomes! These are the early days of a revolution in the treatment of CNS diseases. The wonderful thing is the PREVENTION of these diseases getting to their later terrible stages. And the positive effect on the entire body...the potential is mind boggling! It reminds me of the impact of statins...only safer and more wide ranging!

Because they restricted those patients who qualified by inclusion/exclusion criteria by requiring an additional hoop they had to jump through of a very tight AB42/40 ratio window that resulted in 80% of qualifying AD patients to be dismissed. We don't really know how leqembi would do in a truly representative population of AD patients with APOE4.

Touching a nerve, eh?

I’ve provided ample proof that Ern is dead. You seem to always have a problem admitting to being wrong, like for example when you predict ABSOLUTELY GREAT NEWS next week and then it doesn’t happen. Your behavior is very Trumpian. Did you learn to never admit a mistake from Trump? I guess so. He’d be so proud of you!

I’ll say it again. The woman in the video, who is named, is the same person who appeared in the obituary. And, the woman who is pictured in the video and the image of the woman in the obituary are the same.

Ern died sometime before his wife. He was listed in her obituary as deceased. Thus, he is not currently taking Blarcamesine.

Again, one video proves nothing about Blarcamesine. Ern could have had a spontaneous if short-lived recovery. He could also have been taking other medication and/or getting supportive care. We don’t know and probably never will. Just admit it. Either way, the video will not be considered as evidence by regulators and no investor should buy the stock purely based on your deceptive use of a dead man.

Lying about a dead man in order to pump the stock for your benefit is shameful and dishonest. Posters may be getting tired this back and forth but to me it’s important to keep calling you out.

Good luck and ERN is dead.

As I recall, Leqembi is reported to have an overall 27 percent efficacy improvement, with APOE4/APOE4 carriers at 21 percent and the remaining participants at 41 percent. The arithmetic indicates that only 30 percent of the trial participants benefited by 41 percent.

I think April 25th is the projected date for clock stop #1 to start. The company then has 90 days to reply. That 90 days can be longer if the company requests it and the EMA agrees.

Narcissists never want to be helpful. They think it puts them one down.

You are an outright liar, You have never ever post an obituary for Margaret Heaven or Ern Heaven.

Ern Heaven and Margaret Heaven are bothe still alive and Ern Heaven is still taking blarcamesine each and every day.



Good luck and GOD bless,

The Five Blarcamesine Success Factors
My understanding is that blarcamesine benefits all patients ....but some more than others depending on their genetics. But I see no sign of blarcamesine doing harm! ... I also understand that there are a growing number of tests that can reliably identify early patients. And these will certainly be very reasonably priced....particularly when compared to the cost of care for an Alzheimer's patient!
You nailed it. Exactly.

1. First, compared to any and all other Alzheimer’s therapies, blarcamesine is, far and away, the safest. Simply, no brain bleeds. No brain shrinkage (the opposite; preservation of brain size) ... etc. No adverse events (severe or obviating side effects).

2. There are patient genotypes that both favor and reduce blarcamesine therapeutic efficacies. Nonetheless, with carefully titrated, optimized dosings, virtually all Alzheimer’s victims can benefit greatly with blarcamesine. Symptoms are either reduced, delayed, or profoundly obviated.

3. Any or all of the new tests for a person’s vulnerability to be afflicted by the future onset of Alzheimer’s disease will be used to institute blarcamesine therapy before any actual symptoms appear, allowing the drug to propitiously interfere, at the start, with the disease’s mechanisms of progression; the game-changing blarcamesine Alzheimer’s prophylaxis factor. Prevent, delay, and/or weaken the disease’s initial symptoms.

4. The costs of blarcamesine therapy will be orders of magnitude less than the existing monoclonal antibody therapies. Blarcamesine is a small molecule that is not expensive or complicated to manufacture.

5. Lastly, it will be discovered that people taking blarcamesine to prevent, delay, or weaken the onset of Alzheimer’s also benefit from a number of other health improvements. Blarcamesine’s facilitation of autophagy, the cellular waste-clearing of misfolded proteins, etc., will be discovered to provide broad anti-aging benefits. Eventually, virtually everyone in their 50s will be taking a daily blarcamesine tablet for the rest of their health-improved lives.

In combination, these five blarcamesine traits will make the drug the Alzheimer’s standard of care, SOC. It will make patients healthy. It won’t bankrupt private or governmental health insurance plans.

My understanding is that blarcamesine benefits all patients ....but some more than others depending on their genetics. But I see no sign of blarcamesine doing harm! Mabs other the hand, do considerable harm to all groups...but more harm to some than others. I also understand that there are a growing number of tests that can reliably identify early patients. And these will certainly be very reasonably priced....particularly when compared to the cost of care for an Alzheimer's patient!

The perpetual analysis provided by you is, all large block orders are MOC, or MM doing their job.

Never an institution, yet institutional ownership keeps going up.

Lmao.........

oops....Friday is closed,,,,,,Good Friday no stock market....especially in Europe where many have a very long weekend with Easter Monday closed

Most important is that your wife's detached retina has been fixed and that she is doing well; my wife's eye has improved a lot; glad about that!

As far as the questions you asked, I am UNQUALIFIED to respond other than the information I have been following here for about 3 years. Most important in my mind is that the 50 plus scientists know more than most here on this message board and endorsed $AVXL, plus the data on OLE seemed to be favorable from what I read.

It seems we are in a waiting game until Clock Stop One has ended with the timeline of April 25th estimate....we wait to see if Missling is kind enough to give a reason or hope for approval!

Stay well......on June 28th my wife and I celebrate our 60th Anniversary...Diamonds are forever! I turned 81 on April 9th....so things are lining up.....ha ha

Oh yeah,, I forgot I was born on Easter, too!

🤩

Let me save everyone some time, so expect AVXL to close at or near the high of the day and don't forget the short squeeze will be here by Friday

Right so that should end up approved just as much as A2-73 with time to fineness the results to present to EMA.

Now I am glad I couldn't invest.

So how does the field of potential patients compare when Biogen limited to those with no or only one copy of gene vs bla being restricted to early patients? There have been disagreements here on the board about the cost and degree of difficulty in identifying early patients. 

FO!

That trade was in the spread. So hard to tell who was the counter party.

I'm not sure about that. Put some effort in. Think like an investor, start there.

That's fine, but all the things you list, although very desirable in a treatment, are not results. Maybe the authorities weigh all that against results. I asked in aprevious post how do the drugs compare wrt results. 

On ST badprecog posted..." lequmbi for ApoE4 noncarriers receiving Leqembi demonstrated a 41% reduction in cognitive decline over 18 months .... There is no way they don't approve us for minimum of 70% Sigma wild type with a 49% reduction over 48 weeks." My understanding is that ADCS-ADL is not a relevant measure in early patients.
Mayo has done a lot of detailed comparisons of blarcamesine to the Mabs....have a look at his website.

I guess they didn’t get the misleading’s memo of combining all phases into a single small and short trial, and calling it “possible pivotal trial”. They need to learn from the best biotech crook.

Their P1 and P2 results must've been pretty good to motivate them to conduct a P3.

Certainly not cheap to conduct a P3!

2 more days of slow trading is quite a surprise to me, volume is barely approaching 400,000 shs !!! Citadel and DE Shaw might be involved in some complex strategies when higher trading increases.....like that big 100K block and option hedge collar.

Give me a Mai Tai or Crash and Burn......ha ha

🤔.......hmmm. What does that say about Avanex's better comparisons....no infusions, pill format, no brain bleeding, no travel to a clinic, etc.

Seems like the European Commission is somehow giving in to Biogen's inferior drug to me!

Are we able to compare ADCS-ADL and ADAS-Cog between the two drugs?